DOCSLIB.ORG

Beneficial Aspects of High Dose Intravenous Vitamin C on Patients with COVID-19 Pneumonia in Severe Condition: a Retrospective Case Series Study

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Beneficial Aspects of High Dose Intravenous Vitamin C on Patients with COVID-19 Pneumonia in Severe Condition: a Retrospective Case Series Study 1609 Original Article Beneficial aspects of high dose intravenous vitamin C on patients with COVID-19 pneumonia in severe condition: a retrospective case series study Bing Zhao1#, Yun Ling2#, Jian Li3#, Yibing Peng4, Jun Huang5, Yihui Wang1, Hongping Qu6, Yuan Gao7, Yingchuan Li8, Bijie Hu9, Shuihua Lu10, Hongzhou Lu2, Wenhong Zhang11, Enqiang Mao1 1Emergency Department of Ruijin Hospital, School of Medicine Shanghai Jiao Tong University, Shanghai, China; 2Department of Infectious Disease, Shanghai Public Health Clinical Center, Shanghai, China; 3Clinical Research Center in Ruijin Hospital, School of Medicine Shanghai Jiao Tong University, Shanghai, China; 4Department of Laboratory Medicine, Ruijin Hospital, School of Medicine Shanghai Jiaotong University, Shanghai, China; 5Shanghai Institute of Hypertension, Shanghai, China; 6Department of Critical Care Medicine, Ruijin Hospital, School of Medicine Shanghai Jiao Tong University, Shanghai, China; 7Department of Critical Care Medicine, Renji Hospital, School of Medicine Shanghai Jiaotong University, Shanghai, China; 8Department of Critical Care Medicine, the Sixth People’s Hospital, Shanghai Jiao Tong University, Shanghai, China; 9Department of Infectious Disease, Zhongshan Hospital, Fudan University, Shanghai, China; 10Tuberculosis Department of Shanghai Public Health Clinical Center, Shanghai, China; 11Department of Infectious disease of Shanghai Huashan Hospital, Fudan University, Shanghai, China Contributions: (I) Conception and design: B Zhao, W Zhang, E Mao; (II) Administrative support: W Zhang, E Mao; (III) Provision of study materials or patients: J Huang, Y Peng, Y Wang, H Qu, Y Gao, Y Li, B Hu, S Lu, H Lu; (IV) Collection and assembly of data: Y Ling, J Li, J Huang, Y Peng, Y Wang, H Qu, Y Gao, Y Li, B Hu, S Lu, H Lu; (V) Data analysis and interpretation: Y Ling, J Li; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors. #These authors contributed equally to this work. Correspondence to: Enqiang Mao. Emergency Department of Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Ruijin 2nd Road 197, Shanghai, China. Email: [email protected]; Wenhong Zhang. Department of Infectious Disease of Shanghai Huashan Hospital, Fudan University, Huashan Road 433, Shanghai, China. Email: [email protected]. Background: Coronavirus disease 2019 (COVID-19) is a global public health event without specific therapeutic agents till now. We aim to determine if high dose intravenous vitamin C (HDIVC) was effective for COVID-19 patients in severe condition. Methods: COVID-19 patients admitted in Shanghai Public Health Clinical Center from January 22, 2020 to April 11, 2020 were retrospectively scrolled. The enrolled patients were those with confirmed diagnosis of severe or critical COVID-19 pneumonia, who received HDIVC within 24 hours after disease aggravation. Main clinical outcomes obtained from 3–5 days (day 3) and 7–10 days (day 7) after HDIVC were compared to the ones just before (day 0) HDIVC. Results: Totally, twelve patients were enrolled including six severe [age of mean, 56; interquartile range (IQR), 32–65 years, 3 men] and six critical (age of mean, 63; IQR, 60–82 years, 4 men) patients. The dosage of vitamin C [median (IQR), mg/kg (body weight)/day] were 162.7 (71.1–328.6) for severe and 178.6 (133.3–350.6) for critical patients. By Generalized estimating equation (GEE) model, C-reactive protein (CRP) was found to decrease significantly from day 0 to 3 and 7 (severe: 59.01±37.9, 12.36±22.12, 8.95± 20.4 mg/L; critical: 92.5±41.21, 33.9±30.2, 59.56±41.4 mg/L). Lymphocyte and CD4+ T cell counts in severe patients reached to normal level since day 3. Similar improving trends were observed for PaO2/FiO2 (severe: 209.3±111.7, 313.4±146, 423.3±140.8; critical: 119.9±52.7, 201.8±86.64, 190.5±51.99) and sequential organ failure assessment score (severe: 2.83±1.72, 1.33±1.63, 0.67±1.03; critical: 6.67±2.34, 4.17±2.32, 3.83±2.56). Better improving effect was observed in severe than critical patients after HDIVC. Conclusions: HDIVC might be beneficial in aspects of inflammatory response, immune and organ function for aggravation of COVID-19 patients. Further clinical trials are in warrant. Trial registration: This trial has been retrospectively registered in Chinese Clinical Trail Registry (ChiCTR2000032716) on May 8, 2020. http://www.chictr.org.cn/showproj.aspx?proj=53389. © Annals of Palliative Medicine. All rights reserved. Ann Palliat Med 2021;10(2):1599-1609 | http://dx.doi.org/10.21037/apm-20-1387 1600 Zhao et al. HDIVC for COVID-19 in aggravation Keywords: Coronavirus disease 2019 (COVID-19); vitamin C; aggravation; therapy; C-reactive protein (CRP) Submitted Jul 09, 2020. Accepted for publication Sep 28, 2020. doi: 10.21037/apm-20-1387 View this article at: http://dx.doi.org/10.21037/apm-20-1387 Introduction a cohort of septic patients with ARDS. (II) Its immune enhancing property and the potential anti-virus ability (11), Coronavirus disease 2019 (COVID-19), the infectious which might help for improving lymphopenia, the main illness caused by severe acute respiratory coronavirus 2 characteristic of COVID-19 which was related with (SARS-CoV-2) has become a worldwide heath care crisis severity (12). Also, application of HDIVC in COVID-19 since December 2019 (1,2). The severity of COVID-19 has already got concerns of some scholars (13). Still, is classified into mild, moderate, severe and critical type promotion of HDIVC needs further evidence. on the guideline made by National Health and Family In this retrospective case series study, we made an Planning Commission of the People’s Republic of China (3). observational comparison of outcomes before and after The severe patient is mainly characterized with deteriorated HDIVC in a cohort of severe and critical patients after respiratory function and rapid progression of radiological disease aggravation occurred. The dosage of vitamin lesions, and the critical patient further requires mechanical C [median (IQR)] applied in severe patients was 162.7 ventilation (MV), accompanying with shock or multiple (71.1–328.6) mg/kg (body weight)/day and 178.6 (133.3– organ failure (Table S1). The aged patients and those with 350.6) mg/kg/day in critical patients. The main outcomes pre-existing respiratory, cardiac and diabetic disease appear were mainly divided into inflammatory response, immune to be at high risk of rapid development to severe and critical and organ dysfunction. To the best of our knowledge, type (4). Various methods of respiratory support are the it is the first time to describe the effect of HDIVC on main treatment for the severe and critical patients, especially COVID-19 pneumonia. We present the following article in the situation of disease aggravation. The respiratory according to the STROBE reporting checklist (available at supports are consisted of high flow oxygen therapy, http://dx.doi.org/10.21037/apm-20-1387). noninvasive or invasive MV and extracorporeal membrane oxygenation (ECMO). As effective antiviral therapy is still vacant, the mortality of COVID-19 patients who required Methods MV was reported as high as 66% (5). Therefore, it is Study design and participants important to develop an effective rescue therapy for these patients, especially in the situation of disease aggravation. This study is a retrospective case series study. It was Vitamin C, one of the key antioxidants of the body, conducted in accordance with the amended Declaration has been highlighted recently in the field of critical care of Helsinki (as revised in 2013) and was approved by the medicine (6). High does intravenous vitamin C (HDIVC), institutional ethics board of Ruijin Hospital, Shanghai a new developed method of administration, has been Jiaotong University school of medicine. Oral consents proven to exert beneficial effect in various critical illness were obtained from each enrolled patient. COVID-19 by animal and clinical study (7,8). The rationale for patients admitted in Shanghai public health clinical HDIVC application in the treatment of severe and critical center from January 22, 2020 to April 11, 2020 were COVID-19 patients, as we deemed, relies on (I) its effective retrospectively scrolled. The inclusion criteria were: (I) ability for eliminating the burst of reactive oxygenase age >18 years; (II) patients who was diagnosed with severe species (ROS) and the following cytokine storm (9), which or critical COVID-19 pneumonia. Diagnosis and severity are the basis for acute respiratory distress syndrome (ARDS). classification were based on the guideline made by National The recent CITRIS-ALI study (10) showed HDIVC Health and Family Planning Commission of the People’s (50 mg/kg actual body weight every 6 hours for 96 hours) Republic of China (3) (the specific criteria of severity was reduced 28 day all-cause mortality (29.8% vs. 46.3%) in shown in Table S1). (III) The severe and critical patients © Annals of Palliative Medicine. All rights reserved. Ann Palliat Med 2021;10(2):1599-1609 | http://dx.doi.org/10.21037/apm-20-1387 Annals of Palliative Medicine, Vol 10, No 2 February 2021 1601 suffered with disease aggravation which was defined as All statistical analyses were performed using SAS v. 9.2 (SAS continuous decreasing of PaO2/FiO2 or enlargement of Institute Inc., USA). Two-sided P values of less than 0.05 lung radiological lesion for 1–3 days. (IV) The enrolled were deemed to be statistically significant. patients should accept HDIVC within 24 hours after disease aggravation. The judgement of aggravation occurrence Results and the initiation of HDIVC was performed by Shanghai COVID-19 pneumonia expert group; the dosage of vitamin Patients characteristics C was determined according to the common opinion of A total of twelve COVID-19 patients were enrolled, among expert group based on the previous clinical study and which six of them were classified into severe type, and research work.
Load more

Recommended publications
  • Decreased Serum Ceruloplasmin Levels Characteristically Aggravate Nigral Iron Deposition in Parkinson’S Disease Downloaded From
    doi:10.1093/brain/awq319 Brain 2011: 134; 50–58 | 50 BRAIN A JOURNAL OF NEUROLOGY Decreased serum ceruloplasmin levels characteristically aggravate nigral iron deposition in Parkinson’s disease Downloaded from Lirong Jin,1,* Jian Wang,2,* Lei Zhao,1 Hang Jin,2 Guoqiang Fei,1 Yuwen Zhang,1 Mengsu Zeng2 and Chunjiu Zhong1,3,4 brain.oxfordjournals.org 1 Department of Neurology, Zhongshan Hospital and Shanghai Medical College, Fudan University, Shanghai, China 2 Department of Radiology, Zhongshan Hospital and Shanghai Medical College, Fudan University, Shanghia, China 3 State Key Laboratory of Medical Neurobiology, Shanghai Medical College, Fudan University, Shanghai, China 4 Institutes of Brain Science, Fudan University, Shanghai, China *These authors contributed equally to this work. Correspondence to: Chunjiu Zhong, MD, PhD, at Main Library L610 Lawrence Livermore Nat Lab on January 23, 2011 Department of Neurology, Zhongshan Hospital and Shanghai Medical College, Fudan University, Shanghai, China E-mail: [email protected] Correspondence may also be addressed to: Mengsu Zeng, MD, PhD, E-mail: [email protected] In vivo and post-mortem studies have demonstrated that increased nigral iron content in patients with Parkinson’s disease is a prominent pathophysiological feature. However, the mechanism and risk factors associated with nigral iron deposition in pa- tients with Parkinson’s disease have not been identified and represent a key challenge in understanding its pathogenesis and for its diagnosis. In this study, we assessed iron levels in patients with Parkinson’s disease and in age- and gender-matched control subjects by measuring phase values using magnetic resonance based susceptibility-weighted phase imaging in a 3T magnetic resonance system.
    [Show full text]
  • The 2 Asia Medical Week
    SYNERGIZED INNOVATION & SUSTAINED EVOLUTION THE 2nd ASIA MEDICAL WEEK ASIAN MEDICAL INNOVATION & DEVELOPMENT FORUM 2019 Fudan Zhongshan International Oncology Summit & Annual Conference of Fudan Zhongshan Cancer Center Shanghai / Shenzhen Oct.19-21 2019 ACTIVITIES RECAP 2018 South Korea 2019 Statistics 11 4 4 1000+ 30 81% Sub-Forums Private Sessions Clinial Exchange Visit Attendees Countries & Regions Top Management Presidents, Vice-Presidents, CEOs, Directors or Officers from Governments, MOHs & Hospitals. Overseas Visitors Armenia Australia Bangladesh Belarus Brazil China Egypt France Greece India Indonesia Italy Japan Kazakhstan Kenya Malaysia Myanmar Northern Cyprus Pakistan Philippines Russia Singapore South Korea Sri Lanka Thailand Turkey Ukraine UK US Vietnam Launching Ceremony Dear Professors, We take a great pleasure in inviting you to the 2019 Asian Medical Week, which is held in Shanghai from October 19th to October 21st , 2019. Asia Medical Week is a prominent academic event for promoting medical communication and cooperation in the Asia-Pacific region. With the theme focusing on "Medical Innovation & Development", 2019 Asia Medical Week is dedicated to providing an effective communication platform for international healthcare community and industry to showcase China’s latest oncology, promote sharing for high-quality healthcare resources and advocate high-tech cooperation for modern medicine. Towards a vision of "Collaborative Innovation, Sustainable Progress", Fudan University Zhongshan Hospital and Fudan University Zhong Shan Hospital Cancer Center (FUZSCC) will host the 2019 Asian Medical Week - - Medical Innovation & Development Forum, featuring 2019 Fudan Zhongshan International Oncology Summit, in concurrent with the annual meeting of FUZSCC. To pace the internationalization and development of China healthcare system through in-depth communication and collaboration between Asia-Pacific countries, the program will focus on the newest advances in tumor management and establish “the Belt and Road” Oncology Alliance during the event.
    [Show full text]
  • Enhanced Activities of Blood Thiamine Diphosphatase and Monophosphatase in Alzheimer’S Disease
    RESEARCH ARTICLE Enhanced Activities of Blood Thiamine Diphosphatase and Monophosphatase in Alzheimer's Disease Xiaoli Pan1,2☯, Shaoming Sang1,2☯, Guoqiang Fei1, Lirong Jin1, Huimin Liu2, Zhiliang Wang3, Hui Wang3, Chunjiu Zhong1,2* 1 Department of Neurology, Zhongshan Hospital & Shanghai Medical College, Fudan University, Shanghai, China, 2 State Key Laboratory of Medical Neurobiology, Institutes of Brain Science & Collaborative Innovation Center for Brain Science, Fudan University, Shanghai, China, 3 Regional Health Service Center of a11111 Xujiahui, Xuhui District, Shanghai, China ☯ These authors contributed equally to this work. * [email protected] Abstract OPEN ACCESS Citation: Pan X, Sang S, Fei G, Jin L, Liu H, Wang Z, et al. (2017) Enhanced Activities of Blood Background Thiamine Diphosphatase and Monophosphatase in Thiamine metabolites and activities of thiamine-dependent enzymes are impaired in Alzhei- Alzheimer's Disease. PLoS ONE 12(1): e0167273. mer's disease (AD). doi:10.1371/journal.pone.0167273 Editor: Marie-Claude Potier, Institut du cerveau et de la moelle epiniere, FRANCE Objective Received: April 17, 2016 To clarify the mechanism for the reduction of thiamine diphosphate (TDP), an active form of Accepted: November 12, 2016 thiamine and critical coenzyme of glucose metabolism, in AD. Published: January 6, 2017 Copyright: © 2017 Pan et al. This is an open access Methods article distributed under the terms of the Creative Forty-five AD patients clinically diagnosed and 38 age- and gender-matched control sub- Commons Attribution License, which permits unrestricted use, distribution, and reproduction in jects without dementia were voluntarily recruited. The contents of blood TDP, thiamine any medium, provided the original author and monophosphate (TMP), and thiamine, as well as the activities of thiamine diphosphatase source are credited.
    [Show full text]
  • International Students Guide Book Siping Campus English Version 1.Bank of Communication(交通银行) Add：41 Zhangwu Rd
    International Students Guide Book Siping Campus English Version 1 International Students Guide Book Siping Campus English Version Foreword Hello! Welcome to Tongji University! We wrote this guide book for you to help you with your life on campus and even in Shanghai. It contains some useful information that you may need in your study and daily life. Hope it can really do some help and wish you enjoy your life here! Group member： Ding Weiling (School of Political Science & International Relations) Dai Haocheng (College of Electronics & Information Engineering) Yu Zhenghao (College of Design & Innovation) Zhang Pei (Law school) April. 2017 2 International Students Guide Book Siping Campus English Version Contents First Arrived in Shanghai Overview of Shanghai 6 Overview of Tongji University 6 Legal Residence 7 Campus Life Student ID Card 15 Study 17 Dining 23 Medical Care 25 Network Communication 27 Traffic 30 Sports 32 School Stores & Shops 34 Activities 35 Useful Apps 36 Around the Campus Public Transportation 39 Banking 43 Shopping & Recreation 45 Campus Map 48 3 International Students Guide Book Siping Campus English Version Contents for Important Pictures Temporary Accommodation 13 Pharmacy around the Campus 27 Metro Stations around the Campus 40 Shanghai Metro Map 41 Bus Stations around the Campus 42 Banks & ATMs around the Campus 44 Campus Map 48 4 International Students Guide Book Siping Campus English Version First Arrived in Shanghai Overview of Shanghai 6 Overview of Tongji University 6 Legal Residence 7 5 International Students Guide Book Siping Campus English Version Overview of Shanghai Shanghai, once a humble fishing village, is now the economic, financial, trade and shipping center of China.
    [Show full text]
  • Cross-Culture Research for Developing WHO Self-Assessment
    Cross-Culture Research for Developing (Chinese version) WHO Self-Assessment tool for Health Promotion in Hospital Objectives Through cross-culture research to develop a Chinese version WHO self-assessment tool for Health Promotion in Hospital; Explore a high effective health care service model through developing health promotion in hospital; Discuss the strategies for HPH development in undeveloped region. Context Why the different conditions and resources makes the similar health promotion result between China and U.S Total expenditure on health per 83 The Unite State capita (Intl $, WHO,2006) Canada 6714 80 China 78 75 75 3672 72 342 Female Male The Unite Canada China Life expectancy at State birth(years) What are the differences between China and Unite State for developing HPH China The Unite State 1. Poor HPH condition Excellent HPH condition and and resource resource 2. Poor medical service Advanced medical service management system management system 3. Serious shortage of Excellent health service health service resource support system and resource 4. Poor public health developing condition Advanced public health and resource developing condition and resource What are the different HPH developing conditions between China and the Unite State China The Unite State Developed Country 1. Undeveloped country, Gross national income Gross national income per per capita (PPP capita (PPP international international $): 4,660 $): 44,070 2. 1.3billion population 0.3billion population 3. Polluted environment Healthy environment The different
    [Show full text]
  • Shanghai Guide
    “YOUR NAME HERE” …and your logo here. We hope you find this guide useful. If you wish to put your company’s name on it and publish we have a number of options for you. Please contact us at [email protected] “Committed to making you feel at home” Shanghai Guide For any specific information or enquires, please contact us Your address here E-mail: [email protected] Website: http://www.wwwaldron.com “YOUR NAME HERE” CONTACT [email protected] FOR MORE INFO. Welcome to Shanghai “YOUR NAME HERE” extends its most sincere welcome to you and to the members of your family who may be accompanying you on your assignment to Shanghai. Leaving home, family and friends behind to move to a new and perhaps completely unfamiliar place can be a difficult experience. It can however, be an exciting and rewarding time - new experiences and acquaintances await you. We in “YOUR NAME HERE” are here to guide and assist you through each and every step of your relocation to ensure a smooth transition to the new life that awaits you in Shanghai. This Relocation Guidebook has been developed as a useful and informative tool to provide answers to many of the questions that you and your family may have as you begin the resettlement process. We have included different sections including topics like housing, medicals, schools, transportation, etc. We have also included many places for food and drink, recreation, shopping, and weekend activities. This guidebook has been carefully prepared to give you all the information and more that you may ever need to help you settle into the Shanghai way of life.
    [Show full text]
  • Gastrointestinal (Colorectal and Anal)
    GASTROINTESTINAL CANCER—COLORECTAL AND ANAL 3500 Oral Abstract Session Final overall survival for the phase III KN177 study: Pembrolizumab versus chemotherapy in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC). Thierry Andre, Kai-Keen Shiu, Tae Won Kim, Benny Vittrup Jensen, Lars Henrik Jensen, Cornelis J. A. Punt, Denis Michel Smith, Rocio Garcia-Carbonero, Julia Alcaide, Peter Gibbs, Christelle De La Fouchardiere, Fernando Rivera, Elena Elez, Johanna C. Bendell, Dung T. Le, Takayuki Yoshino, Wen Yan Zhong, David R. Fogelman, Patricia Marinello, Luis A. Diaz; Sorbonne Universite� and Ho^pital- Saint Antoine, Paris, France; University College Hospital, NHS Foundation Trust, London, United King- dom; Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea; Herlev and Gentofte Hospital, Herlev, Denmark; University Hospital of Southern Denmark, Vejle, Denmark; Depart- ment of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, Amsterdam, Netherlands; Bordeaux University Hospital, Bordeaux, France; Hospital Universitario 12 de Octubre, Imas12, CNIO, UCM, Madrid, Spain; Hospital Regional Universitario de Malaga, Ma�laga, Spain; Western Health, St. Al- bans, Australia; Centre Le�on Be�rard, Lyon, France; Hospital Universitario Marque�s de Valdecilla, IDIV- AL, Santander, Spain; Vall dHebron Institute of Oncology, Barcelona, Spain; Sarah Cannon Research Institute/Tennessee Oncology PLLC, Nashville, TN; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; National Cancer Center Hospital East, Kashiwa, Japan; MSD China, Shanghai, China; Merck & Co., Inc., Kenilworth, NJ; Memorial Sloan Kettering Cancer Center, New York, NY Background: In the phase III, randomized open-label KEYNOTE-177 (NCT02563002) study 1L pem- brolizumab (pembro) versus chemotherapy (chemo) provided superior progression-free survival (PFS) at second interim analysis (IA2) in patients (pts) with MSI-H/dMMR mCRC.
    [Show full text]
  • Famous Hospitals in Shanghai City
    Famous Hospitals in Shanghai City Franco Naccarella Medical service system and pertinent bureau • There are four medical service systems in Shanghai. • They are Fu Dan University, Shanghai Jiao Tong University, Tong Jing University, Shanghai Traditional Chinese Medical School • Shanghai Bureau of health make the rule of hearth care and supervise all the hospitals attached to their university. Top Ten Hospital Fudan University • Zhongshan Hospital • Huashan Hospital Shanghai Jiao Tong University • First People’s Hospital • Sixth People’s Hospital • Renji Hospital • Ruijin Hospital • Xinhua Hospital • Nineth People’s Hospital Second Military Medical University • Changhai Hospital • Changzheng Hospital Zhongshan hospital Zhongshan hospital • Zhongshan Hospital was founded in 1936 in commemoration of the late Dr. Sun Yat- sen. It is a leading hospital in China and was awarded "The Best 100 Hospitals" in 1999 • The discipline of Zhongshan Hospital is Prudent, Practicality, Unity and Offering Zhongshan hospital www.zs-hospital.sh.cn • Cardiology, Hepatology,Nephrology and Respiratory diseases are their leading subject • Cardiology research institute is well known in the world. They performed the first cardiac catheter examination in China Zhongshan hospital • Cardiology department is the largest in Shanghai area. They have three catheter room, non-invasive cardiac exam center including treadmill exercise test, tilt table test, holter monitor, ABPM and advanced Echo center. • EP center have sophisticated EP console. They own CARTO-XP 3 dimension electroanatomy mapping equipment Zhongshan hospital • Their emergency PCI number is the largest in Shanghai area, about 400 cases for one year, and more than 1000 cases of selective PCI cases every year • The cardiolog department is also well known for myocardiopathy and myocarditis research • They are number of national qualified clinical medicine trial base and national EP training base Zhongshan hospital • The chief of cardiolgy is prof.
    [Show full text]
  • A Time-Series Panel Study
    Science of the Total Environment 619–620 (2018) 360–365 Contents lists available at ScienceDirect Science of the Total Environment journal homepage: www.elsevier.com/locate/scitotenv Effects of ambient temperature on lung function in patients with chronic obstructive pulmonary disease: A time-series panel study Zhijing Lin a,1, Yutong Gu b,1,CongLiua,YuanlinSongb, Chunxue Bai b,RenjieChena,c,⁎, Shujing Chen b,⁎⁎,HaidongKana a School of Public Health, Key Lab of Public Health Safety of the Ministry of Education and Key Lab of Health Technology Assessment of the Ministry of Health, Fudan University, Shanghai 200032, China b Department of Pulmonary Medicine, Zhongshan Hospital, Fudan University, Shanghai 200032, China c Shanghai Key Laboratory of Meteorology and Health, Shanghai 200030, China HIGHLIGHTS GRAPHICAL ABSTRACT • This is a time-series panel study with in- tensive daily lung function measure- ments. • The associations between daily temper- ature and PEF were inverted U–shaped. • Both low and high temperatures were significantly associated with reduced PEF. • No apparent associations were observed for temperature and FEV1. article info abstract Article history: Background: Limited evidence concerns the associations between ambient temperature and lung function and Received 27 April 2017 the results are mixed. Received in revised form 3 November 2017 Objective: To evaluate the associations between temperature variations and daily fluctuations in pulmonary func- Accepted 3 November 2017 tion in chronic obstructive pulmonary disease (COPD) patients. Available online xxxx Methods: We designed a time-series panel study of 28 male urban COPD patients with repeated daily lung func- tion measurements from December 2012 to May 2013 in Shanghai, China.
    [Show full text]
  • Surgical Fixation of Rib Fractures Decreases Intensive Care Length of Stay in Flail Chest Patients
    216 Original Article Page 1 of 9 Surgical fixation of rib fractures decreases intensive care length of stay in flail chest patients Xiangzhi Xiao1#, Shengchao Zhang1#, Juhua Yang1, Jian Wang2, Zhilong Zhang2, Hao Chen1,2 1Department of Thoracic Surgery, Qingpu Branch of Zhongshan Hospital, Fudan University, Shanghai 201700, China; 2Department of Thoracic Surgery, Xuhui Branch of Zhongshan Hospital, Fudan University, Shanghai 200031, China Contributions: (I) Conception and design: X Xiao, S Zhang, H Chen; (II) Administrative support: J Yang; (III) Provision of study materials or patients: X Xiao, S Zhang, J Yang, H Chen; (IV) Collection and assembly of data: All authors; (V) Data analysis and interpretation: All authors; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors. #These authors contributed equally to this work. Correspondence to: Hao Chen, MD, PhD. Department of Thoracic Surgery, Xuhui Branch of Zhongshan Hospital, Fudan University, 966 Middle Huaihai Road, Shanghai 200031, China. Email: [email protected]. Background: Nonoperative treatment is currently the standard therapy for rib fractures. However, there is a trend towards surgical fixation from conservative management over the last decade. While surgical fixation of rib fractures has shown promising results, its impact on the clinical results remains unclear based on the current literature. As such, the present study aims to compare the short-term outcomes of multiple rib fracture patients treated by surgical fixation with traditional conservative management. Methods: Data for patients with multiple (three or more) rib fractures admitted to our department between January 2012 and January 2019 were retrospectively collected and analyzed. Propensity score matched patients were compared between those treated with surgical rib fixation and those of nonoperatively treated.
    [Show full text]
  • NCI Designated Cancer Centers International Activities
    International Activities of NCI-Designated Cancer Centers Summary Report March 2014 This report is not a comprehensive summary of the international efforts of NCI-Designated Cancer Centers and not all of the efforts outlined in this report are NCI or NIH-funded. Rather, this report summarizes information that was provided by Cancer Centers who responded to requests from the NCI Center for Global Health for information on international activities. This is an ongoing data- collection effort, the data collection status for individual cancer centers can be found in Appendix A. Any additions or corrections are welcome. Please contact Rebecca Minneman ([email protected]). Table of Contents Abramson Cancer Center - University of Pennsylvania ....................................................................................4 Albert Einstein Cancer Center - Yeshiva University ..........................................................................................4 Alvin J. Siteman Cancer Center - Washington University ..................................................................................5 The Barbara Ann Karmanos Cancer Institute – Wayne State University ............................................................6 The Cancer Therapy & Research Center (CTRC) at the University of Texas Health Science Center at San Antonio (UTHSCSA) ................................................................................................................................................... 10 Case Comprehensive Cancer Center - Case Western
    [Show full text]
  • Qingpu District, Shanghai
    Research Report on the Investment Environment of Qingpu District, Shanghai About Deloitte Deloitte refers to one or more of Deloitte Touche Tohmatsu Limited (“DTTL”), its global network of member firms, and their related entities. DTTL (also referred to as “Deloitte Global”) and each of its member firms and their affiliated entities are legally separate and independent entities. DTTL does not provide services to clients. Please see www.deloitte.com/about to learn more. Deloitte Asia Pacific Limited is a company limited by guarantee and a member firm of DTTL. Members of Deloitte Asia Pacific Limited and their related entities, each of which are separate and independent legal entities, provide services from more than 100 cities across the region, including Auckland, Bangkok, Beijing, Hanoi, Hong Kong, Jakarta, Kuala Lumpur, Manila, Melbourne, Osaka, Shanghai, Singapore, Sydney, Taipei and Tokyo. The Deloitte brand entered the China market in 1917 with the opening of an office in Shanghai. Today, Deloitte China delivers a comprehensive range of audit & assurance, consulting, financial advisory, risk advisory and tax services to local, multinational and growth enterprise clients in China. Deloitte China has also made—and continues to make—substantial contributions to the development of China's accounting standards, taxation system and professional expertise. Deloitte China is a locally incorporated professional services organization, owned by its partners in China. To learn more about how Deloitte makes an Impact that Matters in China, please connect with our social media platforms at www2.deloitte.com/cn/ en/social-media. This communication contains general information only, and none of Deloitte Touche Tohmatsu Limited, its member firms, or their related entities (collectively the “Deloitte Network”) is by means of this communication, rendering professional advice or services.
    [Show full text]